MaxiVax S.A.

https://www.maxivax.ch

MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. The company received the 2017 CTI Swiss Medtech Award for its groundbreaking work, and its lead product MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland. The company successfully filed an IND with the US FDA in 2018. *

	Start	2005-12-20 established
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	MVX-ONCO-1 (MaxiVax)
	Person	Goundis, Dimitri (MaxiVax 201602– CEO before Acrongenomics + Speedel + Medicines Co Inc + Roche)

	Region	Genève (Geneva) GE
	Country	Switzerland
	Street	24 rue de l’Athénée
	City	1206 Genève GE
	Tel	+41-22-552-2613
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: MaxiVax S.A.. (9/25/18). "Press Release: MaxiVax Starts Phase 2 Study in Switzerland of Innovative Cancer Vaccine in Patients with Head & Neck Cancer". Geneva.

		Record changed: 2019-11-27

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for MaxiVax S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]